Header

Solid Tumor/Phase I Clinical Trials

Category:Adult
Status:Active

Displaying Trial 1 - 30 of 111 in total

An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification

This is an open-label, multicenter, multinational, Phase 2 study exploring the efficacy and safety of neratinib therapy in patients with solid tumors with activating HER2, HER3 or EGFR mutations or...

Diagnosis: Solid Tumor/Phase I

Phase: 2

Protocol Number: 13-615

Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors (NAVIGATE)

Phase II, multi-center, open-label study of patients with advanced solid tumors harboring a fusion of NTRK1, NTRK2 or NTRK3.

Diagnosis: Solid Tumor/Phase I

Phase: 2

Protocol Number:

Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors

This phase Ib/II trial studies the side effects and best dose of trametinib and navitoclax in treating patients with solid tumors that have spread to other places in the body or cannot be cured or ...

Diagnosis: Solid Tumor/Phase I

Phase: 1 / 2

Protocol Number: 13-505

Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkins Lymphoma

The purpose of this study is to determine which doses of Urelumab and Nivolumab are safe and tolerable when they are given together.

Diagnosis: Solid Tumor/Phase I, Non-Hodgkin's Lymphoma

Phase: 1 / 2

Protocol Number: 15-207

A Study to Investigate the Safety and Efficacy of Nivolumab and Nivolumab Plus Ipilimumab in Virus-associated Tumors

The purpose of this study to investigate the safety and efficacy of using nivolumab, and nivolumab in combination with ipilimumab, to treat subjects who have virus-associated tumors. Certain viruse...

Diagnosis: Solid Tumor/Phase I

Phase: 1 / 2

Protocol Number: 15-423

Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

The purpose of this first-in-human study of MBG453 is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of MBG453 administered i.v. as a single ag...

Diagnosis: Solid Tumor/Phase I

Phase: 1 / 2

Protocol Number: 16-214

Study CB-839 in Combination With Nivolumab in Patients With ccRCC and Other Solid Tumors

This study is an open-label Phase 1/ 2 evaluation of CB-839 in combination with nivolumab in patients with clear cell renal cell carcinoma, melanoma, and non-small cell lung cancer.

Diagnosis: Solid Tumor/Phase I

Phase: 1 / 2

Protocol Number: 16-379

A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors

The primary objective of this study is to determine the maximum tolerated dose (MTD) or recommended phase II doses of sapacitabine and seliciclib administered sequentially or concomitantly. The sec...

Diagnosis: Solid Tumor/Phase I

Phase: 1

Protocol Number: 08-271

Safety Study of MGA271 in Refractory Cancer

The purpose of this study is to evaluate the safety of MGA271 when given by intravenous (IV) infusion to patients with refractory cancer. The study will also evaluate how long MGA271 stays in the b...

Diagnosis: Solid Tumor/Phase I

Phase: 1

Protocol Number: 11-217

Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors

This phase I trial studies the side effects and the best dose of veliparib and dinaciclib in treating patients with solid tumors that have spread to other places in the body and usually cannot be c...

Diagnosis: Solid Tumor/Phase I

Phase: 1

Protocol Number: 11-144

Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations

This study is primarily designed to assess the safety and the tolerability of Debio1347 (CH5183284) in patients with advanced solid malignancies, whose tumours have an alteration of the Fibroblast ...

Diagnosis: Solid Tumor/Phase I

Phase: 1

Protocol Number: 13-251

Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors

To assess the safety and tolerability, characterize the dose-limiting toxicities, and identify the maximum tolerated dose of BMS-986016 alone and in combination with Nivolumab in subjects with sele...

Diagnosis: Solid Tumor/Phase I

Phase: 1

Protocol Number:

Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid Tumors

This phase I trial studies the side effects and best dose of ziv-aflibercept when given together with pembrolizumab in treating patients with solid tumors that have spread to other places in the bo...

Diagnosis: Solid Tumor/Phase I

Phase: 1

Protocol Number: 15-703

A Phase 1B Study of MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Patients With Advanced Nonhematologic Malignancies

The primary purpose of this study is to determine the safety profile and the maximum tolerated doses (MTDs/potential recommended phase 2 doses (RP2Ds) of the combination treatments of MLN2480 + MLN...

Diagnosis: Solid Tumor/Phase I

Phase: 1

Protocol Number: 14-537

A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers

This is an open-label, single arm, dose escalation study in patients with advanced cancers.

Diagnosis: Solid Tumor/Phase I

Phase: 1

Protocol Number: 15-281

ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas

This study evaluates the anti-tumor effects of ALRN-6924 in patients with advanced solid tumors or lymphomas with WT TP53.

Diagnosis: Lymphoma, Solid Tumor/Phase I

Phase: 1

Protocol Number:

A Study to Evaluate the Safety and Pharmacokinetics of KTN0158 in Adult Patients With Advanced Solid Tumors

This is a dose-escalation Phase 1 study designed to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose, and the safety profile of KTN0158 in patients with KIT-positive advan...

Diagnosis: Solid Tumor/Phase I

Phase: 1

Protocol Number: 15-577

Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination

This screening study is intended for men and women at least 18 years of age who have advanced solid or hematologic malignancy. The study will assess a subject's tumor antigen expression profil...

Diagnosis: Solid Tumor/Phase I

Phase: N/A

Protocol Number: 15-504

AZD8186 First Time In Patient Ascending Dose Study

This is a phase I, open-label, multicentre study of AZD8186 administered orally in patients with advanced castrate-resistant prostate cancer (CRPC), squamous non-small cell lung cancer (sqNSCLC), t...

Diagnosis: Solid Tumor/Phase I

Phase:

Protocol Number: 13-300

Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors

This is an open-label Phase 1b/2 trial of lenvatinib (E7080) plus pembrolizumab in participants with selected solid tumors. Phase 1b will determine and confirm the maximum tolerated dose (MTD) for ...

Diagnosis: Solid Tumor/Phase I

Phase:

Protocol Number: 15-497

Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors

Prospective, open-label, dose-ranging, uncontrolled phase I study with PM01183 in combination with irinotecan to determine the maximum tolerated dose (MTD) and the recommended dose (RD) of PM01183 ...

Diagnosis: Solid Tumor/Phase I

Phase:

Protocol Number: 16-004

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors that have progressed on standard of care therapy will be treated with pembrolizumab.

Diagnosis: Solid Tumor/Phase I

Phase:

Protocol Number: 16-030

A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549

This dose-escalation study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of IPI-549 monotherapy and IPI-549 in combination with pembrolizumab in subjects with advan...

Diagnosis: Solid Tumor/Phase I

Phase:

Protocol Number: 16-008

Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors

This first-in-human open-label, multicenter, dose-escalation study is designed to evaluate the safety, tolerability, and PK of MTIG7192A alone or in combination with atezolizumab in participants wi...

Diagnosis: Solid Tumor/Phase I

Phase:

Protocol Number: 16-251

Study of FPA008 in Combination With Nivolumab in Patients With Selected Advanced Cancers

This is a phase 1a/b single-arm, open-label study to evaluate safety, tolerability, PK, and clinical benefit of FPA008 in combination with nivolumab in patients with selected advanced cancers.

Diagnosis: Solid Tumor/Phase I

Phase:

Protocol Number: 15-572

A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors

The purpose of this study is to evaluate the maximum tolerated dose (MTD) or recommended Phase 2 dose, safety and efficacy of TAK-659 in combination with nivolumab in participants with advanced sol...

Diagnosis: Solid Tumor/Phase I

Phase:

Protocol Number: 16-395

Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors

This is a Phase I, open-label, multi-center trial designed to evaluate the safety, tolerability and pharmacokinetics of CUDC-907 administered orally to subjects with advanced/relapsed solid tumors.

Diagnosis: Solid Tumor/Phase I

Phase:

Protocol Number: 16-286

Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer

The overarching objective of the study is to determine the effectiveness of LMWH/ warfarin vs. DOAC anticoagulation for preventing recurrent VTE in cancer patients. The intervention strategy is Dir...

Diagnosis: Solid Tumor/Phase I, Multiple Myeloma, Lymphoma

Phase:

Protocol Number: 16-406

Study of the Safety and Efficacy of MIW815 (ADU-S100) in Patients With Advanced/Metastatic Solid Tumors or Lymphomas

The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity of MIW815 (ADU-S100) administered via intratumoral injection.

Diagnosis: Solid Tumor/Phase I, Lymphoma

Phase:

Protocol Number: 16-274

Pembrolizumab Combined With INCB039110 and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors

This is an open-label, Phase 1b, 2 Part (Part 1a and Part 1b), multi-center study. Part 1a utilizes a 3+3 design to evaluate pembrolizumab and INCB combinations in advanced solid tumors. Group A wi...

Diagnosis: Solid Tumor/Phase I

Phase:

Protocol Number: 16-194

<< Previous 1 3 4
'